|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Anders CK and Carey LA: Biology,
metastatic patterns, and treatment of patients with triple-negative
breast cancer. Clin Breast Cancer. 9(Suppl 2): S73–S81. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wahba HA and El-Hadaad HA: Current
approaches in treatment of triple-negative breast cancer. Cancer
Biol Med. 12:106–116. 2015.PubMed/NCBI
|
|
4
|
Ismail-Khan R and Bui MM: A review of
triple-negative breast cancer. Cancer Control. 17:173–176.
2010.PubMed/NCBI
|
|
5
|
Ohno T, Nagatsu A, Nakagawa M, Inoue M, Li
YM, Minatoguchi S, Mizukami H and Fujiwara H: New sesquiterpene
lactones from water extract of the root of Lindera strychnifolia
with cytotoxicity against the human small cell lung cancer cell,
SBC-3. Tetrahedron Lett. 46:8657–8660. 2005. View Article : Google Scholar
|
|
6
|
Wang F, Gao Y, Zhang L, Bai B, Hu YN, Dong
ZJ, Zhai QW, Zhu HJ and Liu JK: A pair of windmill-shaped
enantiomers from Lindera aggregata with activity toward improvement
of insulin sensitivity. Org Lett. 12:3196–3199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang F, Gao Y, Zhang L and Liu JK:
Bi-linderone, a highly modified methyl-linderone dimer from Lindera
aggregata with activity toward improvement of insulin sensitivity
in vitro. Org Lett. 12:2354–2357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ohno T, Takemura G, Murata I, Kagawa T,
Akao S, Minatoguchi S, Fujiwara T and Fujiwara H: Water extract of
the root of Lindera strychnifolia slows down the progression of
diabetic nephropathy in db/db mice. Life Sci. 77:1391–1403. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kobayashi W, Miyase T, Sano M, Umehara K,
Warashina T and Noguchi H: Prolyl endopeptidase inhibitors from the
roots of Lindera strychnifolia F. Vill. Biol Pharm Bull.
25:1049–1052. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wong SL, Chang HS, Wang GJ, Chiang MY,
Huang HY, Chen CH, Tsai SC, Lin CH and Chen IS: Secondary
metabolites from the roots of Neolitsea daibuensis and their
anti-inflammatory activity. J Nat Prod. 74:2489–2496. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chang WA, Lin ES, Tsai MJ, Huang MS and
Kuo PL: Isolinderalactone inhibits proliferation of A549 human
non-small cell lung cancer cells by arresting the cell cycle at the
G0/g1 phase and inducing a Fas receptor and
soluble Fas ligand-mediated apoptotic pathway. Mol Med Rep.
9:1653–1659. 2014.PubMed/NCBI
|
|
12
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: A leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang CY, Bai XY and Wang CH: Traditional
Chinese medicine: A treasured natural resource of anticancer drug
research and development. Am J Chin Med. 42:543–559. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gritsko T, Williams A, Turkson J, Kaneko
S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, et al:
Persistent activation of stat3 signaling induces survivin gene
expression and confers resistance to apoptosis in human breast
cancer cells. Clin Cancer Res. 12:11–19. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song H, Wang R, Wang S and Lin J: A
low-molecular-weight compound discovered through virtual database
screening inhibits Stat3 function in breast cancer cells. Proc Natl
Acad Sci USA. 102:4700–4705. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
White CA and Nicola NA: SOCS3: An
essential physiological inhibitor of signaling by interleukin-6 and
G-CSF family cytokines. JAK-STAT. 2:e250452013. View Article : Google Scholar
|
|
17
|
Collins AS, McCoy CE, Lloyd AT, O'Farrelly
C and Stevenson NJ: miR-19a: An effective regulator of SOCS3 and
enhancer of JAK-STAT signalling. PLoS One. 8:e690902013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kneitz B, Krebs M, Kalogirou C, Schubert
M, Joniau S, van Poppel H, Lerut E, Kneitz S, Scholz CJ, Ströbel P,
et al: Survival in patients with high-risk prostate cancer is
predicted by miR-221, which regulates proliferation, apoptosis, and
invasion of prostate cancer cells by inhibiting IRF2 and SOCS3.
Cancer Res. 74:2591–2603. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Patel K, Kollory A, Takashima A, Sarkar S,
Faller DV and Ghosh SK: MicroRNA let-7 downregulates STAT3
phosphorylation in pancreatic cancer cells by increasing SOCS3
expression. Cancer Lett. 347:54–64. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:42015. View Article : Google Scholar
|
|
21
|
Garcia DM, Baek D, Shin C, Bell GW,
Grimson A and Bartel DP: Weak seed-pairing stability and high
target-site abundance decrease the proficiency of lsy-6 and other
microRNAs. Nat Struct Mol Biol. 18:1139–1146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peter ME: Programmed cell death: Apoptosis
meets necrosis. Nature. 471:310–312. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arnoult D, Gaume B, Karbowski M, Sharpe
JC, Cecconi F and Youle RJ: Mitochondrial release of AIF and EndoG
requires caspase activation downstream of Bax/Bak-mediated
permeabilization. EMBO J. 22:4385–4399. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Joza N, Susin SA, Daugas E, Stanford WL,
Cho SK, Li CY, Sasaki T, Elia AJ, Cheng HY, Ravagnan L, et al:
Essential role of the mitochondrial apoptosis-inducing factor in
programmed cell death. Nature. 410:549–554. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li LY, Luo X and Wang X: Endonuclease G is
an apoptotic DNase when released from mitochondria. Nature.
412:95–99. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Takahashi R, Deveraux Q, Tamm I, Welsh K,
Assa-Munt N, Salvesen GS and Reed JC: A single BIR domain of XIAP
sufficient for inhibiting caspases. J Biol Chem. 273:7787–7790.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Obexer P and Ausserlechner MJ: X-linked
inhibitor of apoptosis protein - a critical death resistance
regulator and therapeutic target for personalized cancer therapy.
Front Oncol. 4:1972014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Dev. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
